[go: up one dir, main page]

BR9909598A - Utilização do composto 1'-{4-{1-(4-fluorofenil)-1h-indol-3-il}-1-butil}- espiro {isobenzo-furano-1 (3h, 4-piperidina} ou de um sal farmaceucamente aceitável do mesmo, para a preparação de um medicamento para o tratamento de ataques de pânico - Google Patents

Utilização do composto 1'-{4-{1-(4-fluorofenil)-1h-indol-3-il}-1-butil}- espiro {isobenzo-furano-1 (3h, 4-piperidina} ou de um sal farmaceucamente aceitável do mesmo, para a preparação de um medicamento para o tratamento de ataques de pânico

Info

Publication number
BR9909598A
BR9909598A BR9909598-0A BR9909598A BR9909598A BR 9909598 A BR9909598 A BR 9909598A BR 9909598 A BR9909598 A BR 9909598A BR 9909598 A BR9909598 A BR 9909598A
Authority
BR
Brazil
Prior art keywords
isobenzo
indol
spiro
fluorophenyl
furan
Prior art date
Application number
BR9909598-0A
Other languages
English (en)
Inventor
Connie Sanchez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR9909598A publication Critical patent/BR9909598A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<B>"UTILIZAçãO DO COMPOSTO 1'-[ 4-[1-(4-fluorofenil)-1H-indol-3-il]-1-butil]-espiro [isobenzo-furano-1(3H), 4'-piperidina] OU DE UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, PARA A PREPARAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE ATAQUES DE PâNICO" O composto 1'-[4-[1-(4-fluorofenil)-1H-indol-3-il]-1-butil]-espiro[isobenzo-furano-1(3 H), 4'piperidina] é ativo em modelos proféticos de efeito sobre ataques de pânico e é util para a preparação de um medicamento para doenças associadas com ataques de pânico.
BR9909598-0A 1998-04-07 1999-03-30 Utilização do composto 1'-{4-{1-(4-fluorofenil)-1h-indol-3-il}-1-butil}- espiro {isobenzo-furano-1 (3h, 4-piperidina} ou de um sal farmaceucamente aceitável do mesmo, para a preparação de um medicamento para o tratamento de ataques de pânico BR9909598A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK50198 1998-04-07
PCT/DK1999/000190 WO1999051229A1 (en) 1998-04-07 1999-03-30 Treatment of panic attacks

Publications (1)

Publication Number Publication Date
BR9909598A true BR9909598A (pt) 2000-11-21

Family

ID=8094284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909598-0A BR9909598A (pt) 1998-04-07 1999-03-30 Utilização do composto 1'-{4-{1-(4-fluorofenil)-1h-indol-3-il}-1-butil}- espiro {isobenzo-furano-1 (3h, 4-piperidina} ou de um sal farmaceucamente aceitável do mesmo, para a preparação de um medicamento para o tratamento de ataques de pânico

Country Status (23)

Country Link
US (1) US6262061B1 (pt)
EP (1) EP1069899A1 (pt)
JP (1) JP2002510626A (pt)
KR (1) KR20010042502A (pt)
CN (1) CN1296409A (pt)
AR (1) AR019023A1 (pt)
AU (1) AU3025899A (pt)
BG (1) BG104814A (pt)
BR (1) BR9909598A (pt)
CA (1) CA2325948A1 (pt)
EA (1) EA200001032A1 (pt)
HR (1) HRP20000659A2 (pt)
HU (1) HUP0101706A3 (pt)
ID (1) ID28335A (pt)
IL (1) IL138484A0 (pt)
IS (1) IS5636A (pt)
NO (1) NO20005062L (pt)
PL (1) PL342989A1 (pt)
SK (1) SK14842000A3 (pt)
TR (1) TR200002891T2 (pt)
WO (1) WO1999051229A1 (pt)
YU (1) YU58900A (pt)
ZA (1) ZA200004856B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2343761A1 (en) * 1998-09-15 2000-03-23 Connie Sanchez Treatment of depression
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
NO20005062D0 (no) 2000-10-06
BG104814A (en) 2001-04-30
AU3025899A (en) 1999-10-25
ID28335A (id) 2001-05-10
WO1999051229A1 (en) 1999-10-14
PL342989A1 (en) 2001-07-16
NO20005062L (no) 2000-11-30
IS5636A (is) 2000-09-22
SK14842000A3 (sk) 2001-06-11
CA2325948A1 (en) 1999-10-14
YU58900A (sh) 2002-11-15
HUP0101706A2 (hu) 2001-11-28
HRP20000659A2 (en) 2001-04-30
EA200001032A1 (ru) 2001-04-23
IL138484A0 (en) 2001-10-31
EP1069899A1 (en) 2001-01-24
CN1296409A (zh) 2001-05-23
AR019023A1 (es) 2001-12-26
ZA200004856B (en) 2001-08-29
KR20010042502A (ko) 2001-05-25
US6262061B1 (en) 2001-07-17
JP2002510626A (ja) 2002-04-09
HUP0101706A3 (en) 2003-03-28
TR200002891T2 (tr) 2001-02-21

Similar Documents

Publication Publication Date Title
BR0113200A (pt) Combinação terapêutica
NO20006482L (no) 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
NO964871L (no) Nye agonistforbindelser
BR9813331A (pt) Composto, uso do mesmo, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano que sofra ou esteja sujeito a condições que possam ser melhoradas pela administração de um inibidor da adesão celular mediada pela a4b1, e, resina
DE69311395D1 (de) Sphäroidische Arzneimittelformulierung
SE9401728D0 (sv) New compounds II
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
BR9909598A (pt) Utilização do composto 1&#39;-{4-{1-(4-fluorofenil)-1h-indol-3-il}-1-butil}- espiro {isobenzo-furano-1 (3h, 4-piperidina} ou de um sal farmaceucamente aceitável do mesmo, para a preparação de um medicamento para o tratamento de ataques de pânico
NZ513851A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE227070T1 (de) Tierfalle
IS4174A (is) Ný notkun á lyfjafræðilega viðurkenndu salti
NO995838L (no) Nye heteroetynylenforbindelser og farmasoeytiske og kosmetiske preparater inneholdende de samme
EE200000290A (et) Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks
BR9913964A (pt) Tratamento de depressão
SE9504267D0 (sv) New therapeutic use
BR0008543A (pt) Agente terapêutico para a claudicação intermitente, e, uso de um derivado de piperidina ou de um sal deste farmaceuticamente aceitável
FR2808940B1 (fr) Oscillateur a quartz auto-regule a basse consommation, notamment pour dispositif medical implantable actif tel que stimulateur cardiaque, defibrillateur, cardioverteur et/ou dispositif multisite
AU2001279607A1 (en) Pharmaceutical composition containing 1&#39;-(4-(1-(4-fluorophenyl)-1h-indole-3-yl) -1-butyl)-spiro(isobenzofuran-1(3h),4&#39;-piperidine)
SU1829341A1 (ru) Галогензамещенные n-бензгидрил- n-(трифторацетил) мочевины, проявляющие противосудорожную активность
NO20010984D0 (no) Anvendelse av R(+)-&lt;alfa&gt;-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
Zwislocki et al. Cochlear noise damage: Empirical evidence for the origin of the ‘‘half‐octave shift’’

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.